Serine
Serine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-17A. In addition, it is known to target metabotropic glutamate receptor 4, probable G-protein coupled receptor 34, probable G-protein coupled receptor 174, metabotropic glutamate receptor 6, neutral amino acid transporter B(0), G-protein coupled receptor family C group 6 member A, sodium- and chloride-dependent glycine transporter 2, glutamate receptor ionotropic, NMDA 1, potassium voltage-gated channel subfamily A member 1, glutamate receptor ionotropic, NMDA 2D, glutamate receptor ionotropic, NMDA 2A, metabotropic glutamate receptor 8, metabotropic glutamate receptor 7, toll-like receptor 4, glutamate receptor ionotropic, NMDA 2C, and glutamate receptor ionotropic, NMDA 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| enbrace hr | unapproved drug other | 2023-12-15 |
| enlyte | unapproved drug other | 2022-07-01 |
| kabiven | New Drug Application | 2023-08-02 |
| perikabiven | New Drug Application | 2023-08-07 |
| plenamine | ANDA | 2023-04-21 |
Show 4 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
1735 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 3 | 28 | 38 | 62 | 99 | 228 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 10 | 31 | 50 | 17 | 37 | 140 |
| Healthy volunteers/patients | — | — | — | 113 | 5 | — | 1 | 5 | 124 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 5 | 14 | 37 | 15 | 25 | 92 |
| Covid-19 | D000086382 | — | U07.1 | 6 | 32 | 23 | 6 | 10 | 67 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | 10 | 11 | 33 | 5 | 5 | 64 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | 4 | 5 | 21 | 10 | 18 | 55 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | 10 | 8 | 20 | 11 | 50 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 10 | 16 | 13 | 10 | 46 |
| Coronary artery disease | D003324 | — | I25.1 | — | 4 | 5 | 25 | 11 | 45 |
Show 117 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 11 | 2 | — | 2 | 15 |
| Hereditary angioedemas | D054179 | EFO_0004131 | — | 4 | 3 | 5 | — | 1 | 12 |
| Psychotic disorders | D011618 | — | F20.81 | — | 4 | 2 | — | 2 | 8 |
| Intracranial thrombosis | D020767 | — | — | 1 | 2 | 4 | — | 1 | 7 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | 5 | 3 | — | 1 | 7 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 3 | 1 | — | 2 | 6 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | 1 | — | — | 6 |
| Cerebral hemorrhage | D002543 | — | — | — | 2 | 4 | — | — | 6 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | 1 | — | 3 | 5 |
| Replacement arthroplasty hip | D019644 | — | — | — | 2 | 1 | — | 2 | 5 |
Show 69 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | 3 | 6 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 5 | — | — | — | 6 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 3 | 2 | — | — | — | 4 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | 2 | — | — | 1 | 4 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | 3 | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | 1 | 3 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | 2 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | — | 3 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | 2 | — | — | 1 | 3 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 2 | — | — | 1 | 3 |
Show 59 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | HP_0000855 | E88.819 | 2 | — | — | — | 2 | 4 |
| Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
| Morbid obesity | D009767 | EFO_0001074 | — | 2 | — | — | — | 1 | 3 |
| Drug interactions | D004347 | — | — | 3 | — | — | — | — | 3 |
| Hepatic insufficiency | D048550 | — | — | 3 | — | — | — | — | 3 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | 1 | 2 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | — | — | 1 | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | 1 | — | — | — | 1 | 2 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | 1 | — | — | — | 1 | 2 |
| Biological availability | D001682 | — | — | 2 | — | — | — | — | 2 |
Show 31 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 4 | 4 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 3 | 3 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 2 | 2 |
| Embolic stroke | D000083262 | — | — | — | — | — | — | 2 | 2 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 2 | 2 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
| Thrombophilia | D019851 | — | D68.59 | — | — | — | — | 1 | 1 |
| Oral surgery | D013515 | — | — | — | — | — | — | 1 | 1 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 1 | 1 |
| Oral surgical procedures | D019647 | — | — | — | — | — | — | 1 | 1 |
Show 50 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Serine |
| INN | dexfosfoserine |
| Description | L-serine is the L-enantiomer of serine. It has a role as a human metabolite, an algal metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a serine family amino acid, a proteinogenic amino acid, a L-alpha-amino acid and a serine. It is a conjugate base of a L-serinium. It is a conjugate acid of a L-serinate. It is an enantiomer of a D-serine. It is a tautomer of a L-serine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](CO)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 56-45-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL11298 |
| ChEBI ID | 17115 |
| PubChem CID | 5951 |
| DrugBank | DB00133 |
| UNII ID | VI4F0K069V (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
GRM4
GRM4
GPR34
GPR34
GPR174
GPR174
GRM6
GRM6
SLC1A5
SLC1A5
GPRC6A
GPRC6A
SLC6A5
SLC6A5
GRIN1
GRIN1
KCNA1
KCNA1
GRIN2D
GRIN2D
GRIN2A
GRIN2A
GRM8
GRM8
GRM7
GRM7
TLR4
TLR4
GRIN2C
GRIN2C
GRIN2B
GRIN2B
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 529,459 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aminosyn ii, Enlyte
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,573 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use